FUSION PROTEIN COMPRISING ANTI-MESOTHELIN ANTIBODY, ANTI-CD3 ANTIBODY OR ANTI-EGFR ANTIBODY, BISPECIFIC OR TRISPECIFIC ANTIBODY COMPRISING SAME, AND USES THEREOF

Title:

FUSION PROTEIN COMPRISING ANTI-MESOTHELIN ANTIBODY, ANTI-CD3 ANTIBODY OR ANTI-EGFR ANTIBODY, BISPECIFIC OR TRISPECIFIC ANTIBODY COMPRISING SAME, AND USES THEREOF

Document Type and Number:

WIPO Patent Application WO/2020/204305

Kind Code:

A1

Abstract:

The present invention relates to: a fusion protein comprising a fragment of an anti-mesothelin antibody, an anti-CD3 antibody or an anti-EGFR antibody; a bispecific antibody that is specific to mesothelin and CD3; a trispecific antibody that is specific to mesothelin, CD3 and EGFR; and uses thereof. The bispecific or trispecific antibody according to the present invention can be prepared in a high yield and with high purity, and has excellent tumor killing and growth inhibitory effects, and thus can be effectively used in cancer treatment.

Inventors:

LIM YANGMI (KR)
LEE SHINAI (KR)
WON JONGHWA (KR)
PARK YONG-YEA (KR)
YOON AERIN (KR)
LEE SUA (KR)
LIM OKJAE (KR)
LIM SOJUNG (KR)
KIM MUNKYUNG (KR)

Application Number:

PCT/KR2019/017809

Publication Date:

October 08, 2020

Filing Date:

December 16, 2019

Export Citation:

Click for automatic bibliography generation Help

Assignee:

GREEN CROSS CORP (KR)
MOGAM INST BIOMEDICAL RES (KR)

International Classes:

C07K16/28; A61K39/00; A61P35/00; C07K16/30

Domestic Patent References:

WO2018045090A1

2018-03-08

Foreign References:

KR20180037950A	2018-04-13
US9416190B2	2016-08-16
KR20080077261A	2008-08-21
US9708412B2	2017-07-18

Other References: